See every side of every news story
Published loading...Updated

NATIONAL mpox drug, Ritchie Torres, Amber Ruffin, NBJC on TDOV

Summary by windycitytimes.com
The National Institutes of Health concluded that the antiviral drug tecovirimat, used without other antivirals, did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical trial. The Study of Tecovirimat for Mpox (STOMP) began in September 2022 as part of the U.S. whole-of-government response to the clade II mpox outbreak. STOMP was a randomized international efficacy …
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

windycitytimes.com broke the news in on Friday, April 4, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.